Effect of Early and Delayed Treatment With Remdesivir on Mortality in Patients Hospitalized With COVID-19.

ABSTRACT:

Background

We applied a target trial emulation framework to estimate the association between early and delayed initiation of remdesivir (RDV) with mortality in hospitalized adults between May 1, 2020, and July 31, 2024, with varying coronavirus disease 2019 (COVID-19) clinical severity.

Methods

Using electronic health records in the National COVID Cohort Collaborative (N3C) database, we emulated a sequence of randomized target trials initiated on each of the first 7 days of hospitalization. We identified 373 226 eligible person-trial hospitalizations, of which 53 959 were initiators and 319 267 were noninitiators of RDV treatment. Patients were divided into clinical severity subgroups based on baseline oxygenation, which included no supplemental oxygen (NSO), noninvasive sup

SUBMITTER: Makkar SR 

PROVIDER: S-EPMC11878583 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature